文献速递心脏核医学肿瘤 PET/CT

82Rb PET/CT测定的心肌灌注与血流储备在癌症患者中的长期预后价值

Long-Term Prognostic Value of 82Rb PET/CT-Determined Myocardial Perfusion and Flow Reserve in Cancer Patients.
PubMed 文献 · J Nucl Med · 2023-01-05

回顾性队列纳入221例已知或疑似冠心病(CAD)的癌症患者,采用定量82Rb PET测定静息与药物负荷心肌血流量并计算心肌血流储备(MFR)。随访85.6个月期间120例死亡,MFR、负荷总差评分与癌症分期均与总生存(OS)显著相关;年龄校正Cox多变量分析中MFR与癌症分期仍为独立预后因素,二者联合可增强OS区分度(P < 0.001)。

要点

  • MFR与癌症分期均为OS的独立预后因素,二者联合可增强OS区分度。
  • 5年OS:MFR ≥ 1.97且早期癌症88%,MFR < 1.97且早期癌症53%。
  • 5年OS:MFR ≥ 1.97且晚期癌症33%,MFR < 1.97且晚期癌症13%。

核心结论

  • 在本队列已知或疑似CAD的癌症患者中,定量PET测得的MFR独立于癌症分期对OS具有预后价值。
  • MFR与癌症分期联合可增强OS区分度,提示MFR可改善风险分层,并可能作为提高癌症患者生存的治疗靶点。

研究设计与样本

  • 回顾性队列研究,纳入221例已知或疑似CAD的癌症患者,中位年龄71岁(范围41–92岁),入组时间为2009年6月至2011年1月。
  • 多数患者因围手术期风险评估转诊,采用定量82Rb PET测定静息与药物负荷心肌血流量。
  • 按癌症组织病理学与临床状态分为早期与晚期癌症组,并按心肌灌注负荷总评分、总差评分及计算的MFR进一步分层。
  • 采用Kaplan-Meier估计总生存(OS),Cox比例风险回归识别OS的独立预测因素。

主要发现

  • 随访85.6个月期间共120例死亡。
  • MFR、总差评分与癌症分期均与OS显著相关。
  • 年龄校正Cox多变量分析中,MFR与癌症分期仍为独立预后因素。
  • MFR联合癌症分期增强OS区分度,各组结局差异显著(P < 0.001)。
  • 5年OS为:MFR ≥ 1.97且早期癌症88%,MFR < 1.97且早期癌症53%,MFR ≥ 1.97且晚期癌症33%,MFR < 1.97且晚期癌症13%。

关键数值与推荐

  • MFR分组阈值为1.97(MFR ≥ 1.97与MFR < 1.97)。
  • 5年OS:MFR ≥ 1.97且早期癌症88%,MFR < 1.97且早期癌症53%。
  • 5年OS:MFR ≥ 1.97且晚期癌症33%,MFR < 1.97且晚期癌症13%。
  • 各组结局差异P < 0.001。

临床怎么用

  • 原文结论认为MFR可改善风险分层,并可能作为提高癌症患者生存的治疗靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myocardial flow reserve (MFR), derived from quantitative measurements of myocardial blood flow during PET imaging, provides prognostic information on patients with coronary artery disease (CAD), but it is not known if this also applies to cancer patients with a competing risk for mortality. Methods: To determine the prognostic value of MFR in patients with cancer, we designed a retrospective cohort study comprising 221 patients with known or suspected CAD (median age, 71 y; range, 41-92 y) enrolled between June 2009 and January 2011. Most patients were referred for perioperative risk assessment. Patients underwent measurement of myocardial blood flow at rest and during pharmacologic stress, using quantitative 82Rb PET imaging. They were divided into early-stage versus advanced-stage cancer groups based on cancer histopathology and clinical state and were further stratified by myocardial perfusion summed stress score, summed difference score, and calculated MFR. Overall survival (OS) was assessed using the Kaplan-Meier estimator, and Cox proportional-hazards regression helped identify independent predictors for OS. Results: During a follow-up of 85.6 mo, 120 deaths occurred. MFR, summed difference score, and cancer stage were significantly associated with OS. In the age-adjusted Cox hazard multivariable analysis, MFR and cancer stage remained independent prognostic factors. MFR combined with cancer stage enhanced OS discrimination. The groups had significantly different outcomes (P < 0.001), with 5-y OS of 88% (MFR ≥ 1.97 and early-stage), 53% (MFR < 1.97 and early-stage), 33% (MFR ≥ 1.97 and advanced-stage), and 13% (MFR < 1.97 and advanced-stage). Conclusion: Independent of cancer stage, MFR derived from quantitative PET was prognostic of OS in our cohort of cancer patients with known or suspected CAD. Combining these 2 parameters enhanced discrimination of OS, suggesting that MFR improves risk stratification and may serve as a treatment target to increase survival in cancer patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fox JJ, Mauguen A, Ito K, et al. Long-Term Prognostic Value of 82Rb PET/CT-Determined Myocardial Perfusion and Flow Reserve in Cancer Patients. J Nucl Med. 2023. PMID: 36604182. doi:10.2967/jnumed.122.264795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。